ClinicalTrials.gg
RecruitingNCT06668012DISPALOMAUpdated Feb 3, 2025

A Multicenter, Open, Comparative Study on Vaginal Dysbiosis in Premenopausal Women (DISPALOMA)

An interventional study of Palomacare® vaginal gel is a medical device with CE class IIa. in Vaginal Dysbiosis, sponsored by Procare Health Iberia S.L.. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Procare Health Iberia S.L. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Dysbiosis with a site in Spain — 4 open to participants now, 4 under way, none of them phase 3. Dysbiosis · Spain.

Started
2024
the only one that year
No phase
6 of 14
2 open now
Registered
10th of 14
by date

Among the 14 studies in Dysbiosis with a site in Spain, this one is the only one that started in 2024, is one of 6 with no phase, and was the 10th registered.

Dysbiosis

190 studies on the registry are indexed under Dysbiosis; 67 are open to participants now.

Browse Dysbiosis studies →

Open to participants now

4 of the 14 studies in Dysbiosis with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 43 Dysbiosis studies recruiting now, 15 (35%) set no upper age limit and 25 (58%) stop at 75 or younger; 11 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dysbiosis with a site in Spain, or all of them as a file.
02

Study summary

The hypothesis is raised of improving the status of vagnal microbiota with a non-hormonal topical product in early situations of dysbiosis in which the vaginal pH is elevated and the patient may or may not be symptomatic, in order to try to prevent the appearance of future established vaginal infections.

Read the detailed description

Multicenter, open, comparative study, where all eligible patients with vaginal dysbiosis (vaginal pH >4.5) will be assigned to one of the 3 study groups (1:1:1) according to the randomization list for random assignment to groups B and C:

A. Symptomatic patients: Treatment with Palomacare® vaginal gel for 6 days B. Asymptomatic patients: Treatment with Palomacare® vaginal gel for 6 days C. Asymptomatic patients: Monitored follow-up

2 visits will be made throughout the study: visit 1 (initial visit, between days 9 and 15 of the menstrual cycle) and visit 2 (final visit, within 5 days after the end of treatment or equivalent in the case of the monitored follow-up group, always before the next menstruation).

The study will consist of two phases; the first phase or PILOT, where 30 patients (10 per group) will be included with the intervention of 2 centers, and a second phase or EXTENSION, where 60 additional patients (20 per group) will be included, obtaining a total of 90 patients (30 per group) at the end of the study.

03

Conditions studied

  • Vaginal Dysbiosis

Browse trials for

Keywords

  • Vaginal
  • Palomacare
  • Dysbiosis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 and 45 years of age, inclusive.
  2. Who are attending a gynecological visit for any reason and who are in the first phase of the menstrual cycle, between the end of menstruation and before ovulation (approximately between days 9 and 15).
  3. With regular menstrual cycles of between 24 and 35 days.
  4. Who are able to understand and sign the after the nature of the study has been fully explained to them.
  5. With a vaginal pH higher than 4.5 with or without symptoms

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of another vaginal or vulvar condition that may confuse the interpretation of the response to the product (erosive lichen planus, inflammatory desquamative vaginitis, or contact dermatitis involving the vulvar epithelium).
  2. Diagnosis of cervical intraepithelial neoplasia (CIN), cervical carcinoma, or endometrial neoplasia.
  3. Active genitourinary infections (VVC, N. gonorrhoeae, C. trachomatis, or T. vaginalis) at the time of inclusion or within 15 days prior to inclusion in the study.
  4. Active genital lesions (ulcers or vesicles compatible with herpes or warts) or genital bleeding.
  5. Pregnant patients or in the immediate postpartum period (up to 40 days).
  6. with copper IUD.
  7. Use of oral or topical antibiotics, or vaginal antifungals in the two weeks prior to the initial visit.
  8. Planned therapy.
  9. Decompensated chronic diseases (diabetes, epilepsy, high blood pressure, etc.).
  10. Use of any other experimental drug or device during the 30 days prior to selection.
  11. Formal for the use of the product, such as to any of the components of the study treatments.
  12. Inability, at the discretion of the researcher, to comply with the requirements of the study, either due to follow-up problems or due to psychophysical characteristics.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    A - Symptomatic patients

    Treatment with Palomacare® vaginal gel for 6 days

    Device: Palomacare® vaginal gel is a medical device with CE class IIa.

  • Active comparator
    B - Asymptomatic patients

    Treatment with Palomacare® vaginal gel for 6 days

    Device: Palomacare® vaginal gel is a medical device with CE class IIa.

  • No intervention
    C - Asymptomatic patients

    Monitored follow-up

Interventions

  • DevicePalomacare® vaginal gel is a medical device with CE class IIa.

    The duration of the study for each patient will be approximately 11-12 days and the treatment for groups A and B will be 6 days. In a first pilot study in asymptomatic women, a tendency towards a positive effect on the composition of vaginal fluid was already observed, as assessed by diagnostic tests and classified using a Likert scale. A subsequent study showed that treatment with a different vaginal gel but with an identical concentration of ingredients from Palomacare® vaginal gel, for 21 consecutive days, is able to improve the composition of vaginal fluid. Based on these preliminary data, it is possible to hypothesize that the action of Palomacare® vaginal gel will have a positive effect on the composition of vaginal fluid in patients affected by dysbiosis, whether asymptomatic or not.

06

What researchers measure

Primary outcomes

  1. Effect of Palomacare® vaginal gel on vaginal microbiota (VM)

    To evaluate the effect of Palomacare® vaginal gel on VM, the change in microbial diversity, vaginotype and taxonomic profile of the vaginal microbiome will be analyzed between V1 and V2 in each group.

    Time frame: Through study completion, an average of 12 days

Secondary outcomes

  1. Effect of Palomacare® vaginal gel on symptoms and pH

    To assess the effect of Palomacare® vaginal gel on: * Symptoms (amine odour, leucorrhoea and itching): for each symptom an VAS intensity scale will be used and the time to show changes in each of the symptoms will be assessed by directly asking the patient. * Vaginal pH: vaginal pH refers to the degree of acidity of the vaginal environment. Adequate vaginal pH levels should be between 3.8 - 4.4. However, these vary throughout the woman's cycle and at different stages of life. The researcher will carry out this measurement at visit 1 and visit 2, noting the numerical value of the patient's vaginal pH.

    Time frame: Through study completion, an average of 12 days

  2. Satisfaction with the use of Palomacare® vaginal gel

    To assess the degree of satisfaction regarding the use of Palomacare® vaginal gel using a 5-point Likert scale at visit 2.

    Time frame: Through study completion, an average of 12 days

  3. Safety and tolerability of Palomacare® vaginal gel

    To assess the safety and tolerability of Palomacare® vaginal gel using a 5-point Likert-type scale at visit 2 and by describing the incidence, nature and severity of adverse events (AEs) throughout the study.

    Time frame: Through study completion, an average of 12 days

07

Study locations

2 of 2 sites recruiting
  • Clínica Sagrada Familia
    Barcelona, 08022, Spain
    Recruiting
  • Instituto Palacios de Salud y Medicina de la Mujer
    Madrid, 41720, Spain
    Recruiting
    • Santiago Palacios, MD · Contact
08

References and documents

Individual participant data

Plan to share: No — To be discussed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for May 2025, 5 months after the start.

Of 84 interventional studies with no phase under Dysbiosis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Oct 31, 2024
StartActual
Dec 12, 2024
Primary completionEst.
May 20, 2025
CompletionEst.
May 31, 2025
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06668012
Lead sponsor
Procare Health Iberia S.L.
Responsible party
Sponsor
First posted
Oct 31, 2024
Start date
Dec 12, 2024
Primary completion
May 20, 2025 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Feb 3, 2025

Study contacts

Josep Combalia, MD
Contact
combalia.j@procarehealth.com
+34 93 645 54 41
Dr. Santiago Palacios Gil-Antuñano, MD
principal investigator · Instituto Palacios de Salud y Medicina de la Mujer
Dr. Fernando Losa Domínguez, MD
principal investigator · Clínica Sagrada Familia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion